The molecular basis of the deficiency of a-
The molecular basis of the deficiency of a-L-fucosidase has been investigated in eight patients who had been diagnosed clinically and enzymatically as suffering from the autosomal recessive lysosomal storage disease fucosidosis. None of the patients had a deletion or gross alteration of the a-L-fucosidase gene (FUCAl) . Single strand conformation polymorphism (SSCP) analysis followed by direct sequencing of amplified exons and flanking regions identified putative disease causing mutations in six of the patients, who had severe forms of the disease and very low residual a-L-fucosidase activity and protein. They were a 10 bp deletion in exon 1 (Ell3fs), a 1 bp deletion at position -2 of intron 2 (S216fs), a g-a transition at IVS5+1, point mutations W183X and N329Y in exons 3 and 6, respectively, and a compound allele consisting of a point mutation in the signal peptide in exon 1, P5R, and a 1 bp insertion in exon 6 (Y330fs). One patient in whom an SSCP change was not detected had residual a-Lfucosidase activity and cross reacting protein in the heterozygous range and normal metabolism of metabolites containing fucose in his fibroblasts, consistent with the low activity polymorphism. The eighth patient, who had a partial deficiency of a-L-fucosidase in her fibroblasts and leucocytes at a young age but normal a-Lfucosidase activity and protein at a later age, was homozygous for the common Q281R polymorphism in exon 5. She had no other sequence changes and Kivlin (Peters plus) syndrome has subsequently been diagnosed. The basis of her transient deficiency of a-L-fucosidase is not known. The detection of five novel mutations in six severely affected patients confirms the genetic heterogeneity in fucosidosis.
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Fucosidosis is the lysosomal storage disease resulting from a deficiency of the enzyme a-Lfucosidase (EC.3.2.1.5 1). ' in sodium azide 0.02% (w/v)) was added to each well. The plates were incubated at room temperature overnight and then washed twice with PBS. Then 50 p1 of extracts of sonicated fibroblasts or lymphoblasts which had been diluted to 20 pg/ml, 40 pg/ml, or 80 pg/ml in blocking solution were added with PBS in the control wells. The plates were incubated for 1.5 hours at room temperature then washed four times with PBS. Fifty microlitres of monoclonal rat antihuman a-L-fucosidase IgG,26 diluted 1000 fold in blocking solution, was then added, again using PBS as control. After incubation for 1.5 hours at room temperature the wells were washed four times with PBS. Then 100 p1 of alkaline phosphatase conjugated goat anti-(rat IgG serum), diluted 500 times in blocking solution, was added to each well. The plates were incubated for one hour and then washed four times with PBS, followed by twice with 10 mmol/l diethanolamine, pH 9.5, containing 0.5 Table 2 
Band sizes seen on Southern blot. PvuII 1 = 7.0 kb; 2 = 6.0 kb. BglI 1 = 12.0 kb; 2 = 6.5 kb + 5.5 kb.
streptavidin bead technology as previously described.'9 Exon 3 was analysed using the Stratagene Cyclist Exo-pfu DNA sequencing kit according to the manufacturer's instructions; 200 fmol of PCR product was sequenced using 1 pmol of primer incorporating 10 ,uCi of a5S-dATP and 2. tations. This excluded the occurrence of the previously described large deletion ofthe 3' end of the genes.3 A specific change in the band pattern was observed for DNA from patient 2 on digestion with TaqI. This has been shown previously by us to result from a mutation in the 5' splice site of intron 5.19 The recurrent mutation Q422X, which has been found in 10 patients with the haplotype (2-2) (2-2) (table 4) from six unrelated families"5 was not detected by Southern blotting in our patients 3 and 7 with the same haplotype. This was confirmed by the specific amplification of exons 7 and 8 using primers 15 and 18 in intron 6 and in the 3' non-coding region, respectively (table 1) , and subsequent digestion with EcoRI.
DETECTION OF SEQUENCE CHANGES BY SSCP
The eight exons of FUCAl and their flanking regions were amplified from genomic DNA from patients and controls by PCR using pairs of intronic primers (tables 2 and 3). Amplified material of the expected sizes was obtained for each exon from all the patients, confirming that no gross deletions of the gene were present. All the sequence changes were present in a homozygous form including those in patient 6, who had sequence changes in both exons 1 and 6. No other sequence changes were detected in the amplified exons that were sequenced apart from the CG transversion in exon 5 responsible for the Q281R polymorphism. In some cases, exons in which an SSCP change had not been detected were sequenced but no further sequence changes were found.
Several of the sequence changes abolished or created sites for restriction enzymes in the amplified sequences, permitting confirmation of the presence of the mutations by restriction analysis (table 1). The P5R mutation was shown to be homozygous in patient 6 and heterozygous in both his parents by digestion with HaeIII. A unique HinfI site is created by the W183X mutation in patient 5 and this was exploited to confirm the homozygosity of this mutation in the patient. The splice site mutation in the 5' splice of intron 5 in patient 2 can be detected because it creates a new TaqI site. This mutation was first detected by Southern blotting using this enzyme and can be readily detected by amplifying exon 5 and its flanking regions followed by digestion with TaqI.'9 The presence of the Q281R polymorphism was also confirmed in patients 3, 5, and 7 by digestion of exon 5 with BsaJI.28
EFFECT OF MUTATIONS ON Q-FUCOSIDASE
The a-fucosidase activity in fibroblasts from the patients was measured using the synthetic fluorigenic substrate, 4-methylumbelliferyl a-L-fucopyranoside (table 1) . The two patients, 1 and 7, in whom an SSCP change had not been detected had activities well within or at the bottom of the normal reference range, respectively. In contrast, the six patients in whom a putative mutation had been found had a-fucosidase activity well below the normal reference range. These results suggest that the detected sequence changes had decreased the a-fucosidase activity.
The amount of protein cross reacting with antibodies raised against purified human liver a-fucosidase was measured in two of the fucosidosis patients with negligible residual activity, 4 and 6, and in the two patients, 1 and 7, with high residual activity, using a double antibody ELISA method ( The change from a small neutral to a larger hydrophobic side chain would be expected to disrupt the conformation of this highly conserved region and to affect the a-fucosidase activity. Asparagine 329 is not part of an N-glycosylation sequon. Patient 8 had a severe form of the disease dying at 3 years 4 months but with initial mild symptoms followed by a rapid and fatal deterioration. 31 Patient 6 was homozygous for a missense mutation, P5R, in exon 1 and a single base insertion in exon 6 (Y33OFs). Both his parents are heterozygous for the two mutations, indicating that they are on the same chromosome. Substitution of the neutral and nonpolar amino acid, proline, by the basic and polar amino acid, arginine, would be expected to alter the folding or chemical topography of the polypeptide chain. This substitution is at the first residue of the hydrophobic core of the 22 amino acid signal peptide of a-fucosidase and might be expected to impair the translocation of the nascent preproenzyme through the endoplasmic reticulum membrane. The effect of a mutation in the signal peptide sequence on the intracellular transport of a lysosomal enzyme is not well understood because such mutations are not common. A missense mutation, A20P, in the signal peptide of a-galactosidase has been shown to lead to a moderate decrease in mRNA in an atypical variant of Fabry disease32 and a 1 bp deletion at codon 15 in the signal peptide sequence of iduronate 2-sulphatase has been reported to lead to a mild form of Hunter disease.33 At least three non-pathogenic polymorphisms have been found in the signal peptide sequence of a-L-iduronidase34 and it has been suggested that such polymorphisms may contribute to the normal variation in enzymatic activity or exacerbate the effect of another sequence change in the gene. The other sequence change in the compound mutant allele of patient 6 is the insertion in exon 6 of a thymine leading to a frameshift and the formation of a premature stop codon, TAA, nine amino acids downstream within the exon. This change could lead to loss of enzymatic activity either by the formation of a truncated protein or by exon skipping. Although patient 6 had severe symptoms he survived to 15 years, suggesting that the low residual activity and cross reacting material (6.9%) produced by this compound allele was partially effective.
The g-*a transition at the + 1 position of the 5' donor splice site of exon 5 in patient 2 was shown to be homozygous by family studies. '9 Both parents, who are distantly related, were carriers of the mutation, which cosegregated with the fucosidosis allele in other family members, indicating strongly that this is the disease causing mutation in this family. Calculation of the likelihood of the use of the normal and mutant splice sites, according to Shapiro and Senepathy,35 indicated that the mutation would lower the likelihood score from 86 to 68. Analysis of the sequence of exon 5 did not show any cryptic splice sites with a higher probability of usage than the mutated splice site. Therefore, exon 5 would probably be spliced out leading to a frameshift in the truncated protein or use of a cryptic intronic site, both of which would explain the deficiency of a-fucosidase. The patient is now aged 13.5 years but is deteriorating rapidly.
The second identified splice site mutation was deletion of adenine at position -2 of intron 2 (S216fs) in patient 4. This mutation, which was homozygous in the patient, was predicted to have two possible effects. Firstly, it may affect splicing, but the likelihood score for the use of the splice site only decreased from 94 to 87, suggesting that the alteration to the reading frame would be more important. The frameshift changes the amino acid sequence from SYKPDL to AINLITERM, that is, the creation of a premature stop codon 5 
